For decades, cannabis has been classified by the U.S. government as a Schedule I drug—a label reserved for substances with a high potential for abuse and no accepted medical use. But as science catches up with public sentiment and patient advocacy, a growing number of medical professionals are reconsidering long-held beliefs about marijuana. Among the most high-profile is Dr. Sanjay Gupta, who publicly reversed his opposition to medical cannabis after a deep dive into the research—and into the lives of patients for whom cannabis was life-changing.
A Personal and Professional Shift in Perspective
When Dr. Gupta first evaluated the medical cannabis landscape, he was skeptical. The studies available in the U.S. seemed inconclusive or focused mostly on harm. At the time, he supported federal restrictions and wrote against legalization.
But a global investigation for his documentary Weed changed his mind. By interviewing patients, medical professionals, and researchers around the world, Dr. Gupta realized that he—and the broader medical community—had overlooked key data from international studies and dismissed legitimate patient stories.
One of the most compelling cases that swayed his view was that of Charlotte Figi, a young girl with Dravet syndrome, a severe form of epilepsy. After exhausting all conventional treatments, her parents turned to a high-CBD cannabis oil. The result was dramatic: Charlotte’s seizures, which once numbered in the hundreds per week, dropped to just a handful per month.
The Schedule I Dilemma: A Barrier to Science
Cannabis’s classification as a Schedule I substance has severely limited research in the United States. While thousands of studies have been conducted—many highlighting risks and side effects—comparatively few explore therapeutic potential. That imbalance has contributed to the perception that marijuana is more dangerous than it actually is, and made it harder for patients and doctors to access reliable information.
Moreover, U.S. researchers face significant hurdles just to study the plant. They need to obtain government-grown cannabis from a single authorized facility and secure multiple layers of federal approval, including from the National Institute on Drug Abuse (NIDA)—an agency focused more on harm than therapeutic value.
What the Research Really Says
Contrary to longstanding claims, the evidence shows that cannabis has a relatively low potential for abuse compared to other substances. Estimates suggest 9–10% of adult cannabis users may develop a dependency—far lower than the 25% seen with heroin, or the 30% associated with tobacco.
In addition to epilepsy, cannabis has shown promise for managing neuropathic pain, nausea from chemotherapy, and symptoms related to multiple sclerosis. International research has also explored its potential as an anti-inflammatory, neuroprotective agent, and even in some cancer therapies.
Yet most of these studies remain outside the U.S., due in part to legal and institutional barriers.
Misconceptions and Public Health Considerations
Dr. Gupta’s shift didn’t come without concerns. He still urges caution, especially when it comes to youth access. Studies have suggested that frequent cannabis use in adolescence could interfere with brain development and may be linked to cognitive decline. As with alcohol, he believes cannabis use should be delayed until adulthood.
He also highlights risks associated with edibles and potent concentrates. With varying THC levels and inconsistent labeling, new users may unknowingly overconsume—leading to negative experiences like anxiety, paranoia, or nausea. Responsible product regulation and consumer education are crucial to prevent misuse.
A Different Approach to Pain Management
The opioid crisis has underscored the need for alternative pain treatments. Cannabis offers one such path, particularly for conditions that traditional medications often fail to treat effectively. Prescription opioids remain the standard for severe or chronic pain, but their high risk of addiction and overdose has driven both patients and physicians to look for safer solutions.
Unlike opioids, there are no documented cases of death from cannabis overdose. For patients managing long-term pain, especially those with conditions like fibromyalgia or cancer, medical marijuana could provide relief without the same level of risk.
What Comes Next
In the years since his documentary aired, Dr. Gupta has continued to advocate for medical cannabis research and reform. He acknowledges that marijuana isn’t a miracle drug, but it deserves to be studied and used responsibly where appropriate. The growing number of physicians, patients, and researchers calling for change reflects an urgent need to shift cannabis policy from criminal justice to public health.
His conclusion is clear: withholding a potentially beneficial treatment from patients due to outdated laws or stigma is both unethical and medically irresponsible.
Key Takeaways
- Cannabis was classified as a Schedule I drug not because of conclusive harm, but due to a lack of scientific understanding in 1970—a void that remains partially unfilled today.
- International studies and patient experiences point to significant medical benefits of cannabis, especially in treating epilepsy and chronic pain.
- Cannabis has a lower risk of dependency than many legal substances, and its safety profile makes it a compelling alternative to opioids.
- Barriers to research in the U.S. continue to hinder a full understanding of cannabis’s medical applications.
- Responsible regulation, product consistency, and patient education are essential to ensure safe access as legalization continues to spread.